Safety and efficacy of low-dose intravenous enoxaparin and glycoprotein IIB/IIIa inhibitor therapy during percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 15, Issue 5, 2003, Pages 235-238

  Carnendran, Louis ^b   Borkowski, Robert ^b   Markabawi, Bashar ^b   Warner, Mark F ^a  

^a Harrisburg Medical Associates   (United States)

^b NONE

Author keywords

Anticoagulation; Coronary stents; Percutaneous closure device; Platelet inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; DEVICE; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME; VIRGINIA;

EID: 0037846473     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
2. Rabah MM, Premereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-1395.
3. Kereiakes DJ, Grines CL, Frye E, et al., NICE I and NICE 4 Investigators. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol 2001;13:272-278.
4. Dudek D, Dabrowski M, Ochala A, et al. Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions (Abstr). Am J Cardiol 2000;86(Suppl 18A):15-I.
5. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999;71:273-281.
6. Ferguson J, Antman E, Bates E, et al., for the NICE 3 Investigators. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: The NICE 3 Study (Abstr). Am J Cardiol 2000;86(Suppl 18A):16I.
7. Kereiakes J, Fry E, Barr L, et al. Enoxaparin-abciximab combination for percutaneous coronary intervention: Final results of the NICE 4 Trial (Abstr). Am J Cardiol 2000;86(Suppl 18A):14I.
8. Denardo SJ, Davis KE, Tcheng JE, Reid PR. Extremely low dose heparin with abciximab in coronary intervention: Improved efficacy and decreased bleeding complications using a novel heparin dosing strategy. Circulation 2000;102(Suppl II):II-785.
9. Bovill EG, Terrin ML, Stump DC, et al., for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II trial. Ann IntMed 1991;115:256-265.
10. Fry E. Glycoprotein IIb/IIIa inhibitors and low-molecular weight heparins: A combined role in coronary interventions? Clin Cardiol 2001;24(Suppl I):I-8-I-11.
11. Kereiakes DJ, Fry E, Mathai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "Nice guys finish fast." J Invas Cardiol 2000;12(Suppl A):1A-5A.
12. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.
13. Li Y, Spencer FA, Ball SP, Becker RC. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonist: Potential contributing mechanisms of benefit in acute coronary syndromes. J Thromb Thrombolysis 2000;10:69-76.
14. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
15. The ESPIRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebocontrolled trial. Lancet 2000;356:2037-2044.
16. Topol EJ, Molitemo DJ, Herrmann HC, et al., for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
17. Ferguson JJ. Combining low molecular weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: The NICE 3 story. J Invas Cardiol 2000;12(Suppl E):E10-E13.
18. Madan M, Radhakrishnan S, Pang JT, et al. Optimal anticoagulation and platelet inhibition are achieved when enoxaparin is combined with small molecule GP IIb/IIIa inhibitors during elective percutaneous coronary intervention (Abstr). Circulation 2001;104(Suppl II):II-385.
19. Willett WC, Dietz WH, Colditz GA. Primary care: Guidelines for a healthy weight. N Engl J Med 1999;341:427-434.
20. Duffm DC, Muhlestein JB, Allison SB, et al. Femoral arterial puncture management after percutaneous coronary procedures: A comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices. J Invas Cardiol 2001;13:354-362.
21. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-2835.
22. Brown DL, Fann CSJ, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87:537-541.
23. Bhatt DL, Lincoff AM. Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary interventions: The results of the CRUISE trial. Circulation 2001;104(Suppl II):II-384.